Novo Nordisk entered into a definitive agreement to acquire Emisphere Technologies Inc., a drug delivery company, for $1.35 billion. The company’s proprietary technologies, such as the Eligen SNAC technology, enable oral formulations of therapeutics. The companies have collaborated since 2007 and Emisphere’s drug delivery technology Eligen SNAC is used by Novo Nordisk under an existing licence agreement in the oral formulation of Novo Nordisk’s GLP-1 receptor agonist semaglutide, sold under the...